Apidra 100 U/ml- Solution for Injection in Vial

Manufacturer
Sanofi-Aventis Deutschland GmbH
 
Contents
Insulin glulisine
 
Indication
Diabetes mellitus
 
Instruction
Should be taken with food. Administer w/in 15 min before a meal or w/in 20 min after starting a meal.
 
Drug interaction
Possible absence of hypoglycaemic warning symptoms with β-blockers. Decreased hypoglycaemic effect with corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, phenothiazine derivatives, somatropin, sympathomimetic agents, thyroid hormones, oestrogens, progestins (e.g. in oral contraceptives), protease inhibitors and atypical antipsychotics (e.g. olanzapine and clozapine). Increased hypoglycaemic effect with oral antidiabetic agents, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Decreased insulin resistance with octreotide and lanreotide. Increased risk of wt gain and peripheral oedema with pioglitazone, rosiglitazone. Decreased effect of sermorelin.
 


 Inquiry - Apidra 100 U/ml- Solution for Injection in Vial